Menu Search
Equities

Nurexone Biologic Inc

J90:MUN

Nurexone Biologic Inc

Actions
  • Price (EUR)0.392
  • Today's Change0.00 / 0.00%
  • Shares traded500.00
  • 1 Year change+92.16%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 07:03 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-4.99m
  • Incorporated2011
  • Employees8.00
  • Location
    Nurexone Biologic Inc9 Mezada Street, Bsr 3 Tower, 30 FloorBNEI BRAK 5120109IsraelISR
  • Phone+1 4 164105297
  • Fax+1 4 164105297
  • Websitehttps://nurexone.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.